Granulomatosis with Polyangiitis (GPA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Granulomatosis with Polyangiitis (GPA) Market Outlook
Thelansis’s “Granulomatosis with
Polyangiitis (GPA) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2024 To 2034" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Granulomatosis
with Polyangiitis (GPA) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Granulomatosis
with Polyangiitis (GPA) Overview
Granulomatosis
with Polyangiitis (GPA) is a systemic vasculitis associated with ANCA
(anti-neutrophil cytoplasmic antibody) primarily affecting the respiratory
tract and kidneys. It can manifest at any age, with a higher occurrence between
65 and 74. The condition often presents with general constitutional symptoms
such as fatigue, muscle pain, joint pain, reduced appetite, and weight loss. It
affects various organs, but the upper airway and renal involvement are most
common. In particular, upper airway involvement is characteristic, occurring in
70-100% of cases at the time of diagnosis. It typically manifests as issues in
the nasal and sinus areas, including symptoms like nasal discharge, nosebleeds,
nasal ulcers, perforation of the nasal septum, granulomatous lesions, or damage
to facial cartilage leading to deformities in the nasal bridge, as well as
inflammation in the sinuses or surrounding areas.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment